Nivalis Therapeutics, Inc.
(NASDAQ : NVLS)

( )
NVLS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading NVLS News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.96%164.701.2%$479.34m
GILDGilead Sciences, Inc.
1.31%67.121.0%$477.88m
BIIBBiogen Inc.
3.62%286.891.2%$430.46m
CELGCelgene Corporation
1.92%125.521.1%$374.36m
REGNRegeneron Pharmaceuticals, Inc.
0.13%372.432.7%$322.82m
VRTXVertex Pharmaceuticals Incorporated
-0.33%117.271.8%$289.46m
INCYIncyte Corporation
0.39%124.392.1%$254.11m
ALXNAlexion Pharmaceuticals, Inc.
0.85%120.551.6%$218.34m
ILMNIllumina, Inc.
0.72%181.503.3%$166.56m
TSROTESARO, Inc.
0.94%138.4415.3%$142.12m
NBIXNeurocrine Biosciences, Inc.
3.55%53.624.5%$102.87m
BMRNBioMarin Pharmaceutical Inc.
0.72%94.194.3%$98.65m
KITEKite Pharma, Inc.
-2.04%80.5715.6%$97.22m
CLVSClovis Oncology, Inc.
1.65%57.8618.2%$93.56m
AAgilent Technologies, Inc.
0.70%54.821.6%$87.06m

Company Profile

Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO.